$VRX (Valeant Pharmaceuticals International, Inc.)

$VRX {{ '2016-08-09T13:17:39+0000' | timeago}} • Webcast

$VRX intends to structure the company through three new segments. A durable growth segment representing approx. 50% of the company's revenue, a growth segment representing approx. 30% of revenue that will include the Branded Rx products, and the company's cash generating segment representing approx. 20% of revenue.

$VRX {{ '2017-11-07T19:06:31+0000' | timeago}} • Announcement

$VRX said it will sell Sprout, the subsidiary that produces Addyi-the female libido pill, to a former shareholder of Sprout in exchange for a 6% royalty on global sales of Addyi. The sale is expected to close before the end of 2017. Addyi is the only approved and commercialized product of Sprout.

$VRX {{ '2017-11-07T14:58:15+0000' | timeago}} • Announcement

$VRX said as of Nov. 7, 2017 it reduced its total debt by approx.  $6Bil since the end of 1Q16.  As of Nov. 7, 2017, approx. 80% of the company's debt is fixed rate debt.

$VRX {{ '2017-11-07T14:54:18+0000' | timeago}} • Announcement

$VRX has maintained its guidance for FY17 Adj. EBITDA to $3.60-3.75Bil. The company updated its FY17 revenue to the range of $8.65-8.80Bil from $8.70-8.90Bil.

$VRX {{ '2017-11-07T14:44:01+0000' | timeago}} • Announcement

The debt-ridden drug maker $VRX swung to profit during 3Q17, helped by strong performance in Bausch and Lomb business. Net income was $1.30Bil, or $3.69 per share, versus net loss of $1.22Bil, or $3.49 per share in 3Q16. Total revenue came in at $2.22Bil, down 10%, due to decrease in volume in the U.S. Diversified Products and Branded Rx segments.

$VRX {{ '2017-11-07T14:05:30+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q3 2017 highlights

$VRX {{ '2017-10-10T14:50:38+0000' | timeago}} • Infographic

$VRX's progress towards paying down a huge debt of $5Bil before Feb 2018.

$VRX {{ '2017-09-29T17:50:36+0000' | timeago}} • Announcement

$VRX completed the sale of its iNova Pharmaceuticals business for $930MM in cash. The pharma company intends to use the net proceeds from the sale to repay term loan debt under its Senior Credit Facility.

$VRX {{ '2017-08-08T18:56:32+0000' | timeago}} • Webcast

$VRX cuts FY17 revenue guidance by $200MM to about $8.70-8.90Bil. This reflects the loss of approx. $170MM of Dendreon revenues. The overall reduced outlooks is mostly due to the revised expectation of the struggling Dermatology business.

$VRX {{ '2017-08-08T18:56:03+0000' | timeago}} • Webcast

During 2Q17, $VRX announced the use of cash on hand to redeem $500MM of outstanding senior notes due 2018. Since 1Q16, the company reduced total debt to $4.8Bil. $VRX expects to exceed the commitment of paying down $5Bil of debt from divestiture proceeds and free cash flow before February 2018.

$VRX {{ '2017-08-08T18:54:54+0000' | timeago}} • Webcast

$VRX's dermatology business continues to underperform. To address the challenges, the company has stabilized Derm ASP and have rebranded the business unit as Ortho Dermatologics during 2Q17. The company launched SILIQ on July. 27, 2017 as the new product under this business unit.

$VRX {{ '2017-08-08T14:16:40+0000' | timeago}} • Announcement

For FY17, $VRX lowered its revenue to about $8.70-8.90Bil from $8.90-9.10Bil. The company also plans to exceed commitment to pay down $5Bil in debt from divestiture proceeds and free cash flow before February 2018.

$VRX {{ '2017-08-08T14:07:13+0000' | timeago}} • Announcement

$VRX, Quebec-based drugmaker, reported 8% drop in its 2Q17 revenue to $2.23Bil. This decrease was mainly due to decline in volume and pricing of its U.S. Diversified Products segment. The company's net loss narrowed to $38MM, or $0.11 per share, compared to $302MM or $0.88 per share during 2Q16, mostly due to progress in debt reduction.

$VRX {{ '2017-08-08T12:03:05+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q2 2017 highlights

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$VRX {{ '2017-05-09T13:36:52+0000' | timeago}} • Webcast

$VRX commented that on the gastrointestinal franchise there were some challenges early in 1Q17. The company added that it has dealt with these challenges and added a primary care capability which was critical for the company.

$VRX {{ '2017-05-09T13:23:50+0000' | timeago}} • Webcast

$VRX stated that on a YoY basis in 1Q17, it has seen some brand price increase and was price positive both in the Branded RX and Bausch & Lomb International business. On a constant currency basis, Bausch & Lomb International also had volume growth, but the result was a negative FX.

$VRX {{ '2017-05-09T12:39:56+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q1 2017 highlights

$VRX {{ '2017-05-09T12:15:14+0000' | timeago}} • Announcement

As the drugmaker posted 1Q17 results, $VRX raised its FY17 guidance for non-GAAP EBITDA to $3.60-3.75Bil from previously expected $3.55-3.70Bil. The revised outlook reflects the impact of the sale of the CeraVe, AcneFree and AMBI skincare brands, but not the sale of the Dendreon business expected to close mid-year.

$VRX {{ '2017-05-09T12:12:01+0000' | timeago}} • Announcement

$VRX, whose stock longtime backer Bill Ackman unceremoniously dumped in March this year, delivered $954MM in cash flow from operations in 1Q17. Debt fell by $3.6Bil to $1.3Bil in the quarter, with Bausch Lomb/International segment revenues inching less than 1% up to $1.15Bil. U.S. Diversified Products segment revenues slipped 37% to $355MM.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm

AlphaGraphics you may like